Valeant Pharmaceuticals International Purchase AgreementPurchase Agreement • April 12th, 2010 • Valeant Pharmaceuticals International • Pharmaceutical preparations • New York
Valeant Pharmaceuticals International, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Purchasers named in Schedule I hereto (the “Purchasers”) an aggregate of $400,000,000 principal amount of the 7.625% Senior Notes of the Company due 2020 (the “Securities”). The Securities will be jointly and severally guaranteed (the “Guarantees”) by certain of the Company’s subsidiaries, which initially shall be the same subsidiaries that guarantee the Company’s outstanding 8.375% Senior Notes due 2016 (the “Guarantors”).
Valeant Pharmaceuticals International $400,000,000 7.625% Senior Notes due 2020 unconditionally guaranteed as to the payment of principal, premium, if any, and interest by the Guarantors party hereto Exchange and Registration Rights AgreementExchange and Registration Rights Agreement • April 12th, 2010 • Valeant Pharmaceuticals International • Pharmaceutical preparations • New York
Goldman, Sachs & Co., As Representative of the several Purchasers named in Schedule I to the Purchase Agreement c/o Goldman, Sachs & Co. 200 West Street New York, New York 10282
